The rise of personalised medicine is revolutionizing healthcare, prompting a re-evaluation of tradit...
Read moreNew biosimilar switching regulations prioritise cost-effective options and discount agreements, imp...
Read moreThe Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...
Read moreWe summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...
Read moreFrom 2016, the Innovation Fund has served as an instrument of central health policy to promote new f...
Read more